The information was generated by an EvaluatePharma analysis cited by Pharm Exec magazine.
Pfizer ($45.3 billion in Rx sales)
1. Prevnar 13 ($5.8 billion)
2. Lyrica ($4.97 billion)
3. Ibrance ($4.12 billion
Roche ($44.55 billion in Rx sales)
1. Herceptin ($7.14 billion)
2. Avastin ($7 billion)
3. Rituxan (6.91 billion)
Novartis ($43.48 billion in Rx sales)
1. Gilenya ($3.34 billion)
2. Cosentyx ($2.84 billion)
3. Lucentis ($2.05 billion)
Johnson & Johnson ($38.82 billion in Rx sales)
1. Stelara ($5.16 billion)
2. Remicade ($4.89 billion)
3. Zytiga ($3.5 billion)
Merck & Co. ($37.35 billion in Rx sales)
1. Keytruda ($7.17 billion)
2. Januvia (3.69 billion)
3. Gardasil ($3.15 billion)
Sanofi ($35.12 billion in Rx sales)
1. Lantus ($4.21 billion)
2. Pentacel ($2.07 billion)
3. Fluzone ($2.02 billion)
AbbVie ($32.07 billion in Rx sales)
1. Humira ($19.94 billion)
2. Mavyret ($3.44 billion)
3. Imbruvica ($2.97 billon)
GlaxoSmithKline ($30.65 billion in Rx sales)
1. Triumeq ($3.54 billion)
2. Advair ($3.23 billion)
3. Tivicay ($2.19 billion
Amgen ($22.53 billion in Rx sales)
1. Enbrel ($5.01 billion)
2. Neulasta ($4.48 billion)
3. Prolia ($2.29 billion)
Gilead Sciences ($21.68 billion in Rx sales)
1. Genvoya ($4.62 billion)
2. Truvada ($2.3 billion)
3. Epclusa ($1.97 billion)
More articles on pharmacy:
Sanofi poaches exec from Novartis
Eli Lilly’s migraine drug 1st approved to reduce cluster headaches: 4 notes
EpiPen shortage will drag on: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.